Evidence map›Paper›PMID 41585886›Full record

ArticleFrontiers in pharmacology2025

Berberine suppresses hepatocellular carcinoma progression by blocking IL-4-JAK1-STAT6-mediated M2 polarization of macrophage.

Peng Wang, Yuwen Zhong, Mengkai Li, Qing Liang, Weiyi Jiang, Mengqi Zhuang, Xuecheng Ge, Huixing Li, Yaoshuai Zhang, Yu Qiao and 8 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Peng Wang *Department of Hepatobiliary Medicine, Eastern Hepatobiliary Surgery Hospital, Shanghai, China.
Yuwen Zhong *Shanghai Frontiers Science Center of Drug Target Identification and Delivery, School of Pharmaceutical Sciences, Shanghai Jiao Tong University, Shanghai, China.
Mengkai Li *Shanghai Frontiers Science Center of Drug Target Identification and Delivery, School of Pharmaceutical Sciences, Shanghai Jiao Tong University, Shanghai, China.
Qing Liang *Department of Pharmacy, Shanghai Fifth People's Hospital, Fudan University, Shanghai, China.
Weiyi JiangShanghai Frontiers Science Center of Drug Target Identification and Delivery, School of Pharmaceutical Sciences, Shanghai Jiao Tong University, Shanghai, China.
Mengqi ZhuangDepartment of Hepatobiliary Medicine, Eastern Hepatobiliary Surgery Hospital, Shanghai, China.
Xuecheng GeAnhui Provincial Key Laboratory of Tumor Evolution and Intelligent Diagnosis and Treatment, Department of Medical Oncology, First Affiliated Hospital of Bengbu Medical University, Bengbu Medical University, Bengbu, Anhui, China.
Huixing LiShanghai Frontiers Science Center of Drug Target Identification and Delivery, School of Pharmaceutical Sciences, Shanghai Jiao Tong University, Shanghai, China.
Yaoshuai ZhangShanghai Frontiers Science Center of Drug Target Identification and Delivery, School of Pharmaceutical Sciences, Shanghai Jiao Tong University, Shanghai, China.
Yu QiaoAnhui Provincial Key Laboratory of Tumor Evolution and Intelligent Diagnosis and Treatment, Department of Medical Oncology, First Affiliated Hospital of Bengbu Medical University, Bengbu Medical University, Bengbu, Anhui, China.
Jiayao JiangShanghai Frontiers Science Center of Drug Target Identification and Delivery, School of Pharmaceutical Sciences, Shanghai Jiao Tong University, Shanghai, China.
Heping HuDepartment of Hepatobiliary Medicine, Eastern Hepatobiliary Surgery Hospital, Shanghai, China.
Wendi LiuDepartment of Hepatobiliary Medicine, Eastern Hepatobiliary Surgery Hospital, Shanghai, China.
Feng QianShanghai Frontiers Science Center of Drug Target Identification and Delivery, School of Pharmaceutical Sciences, Shanghai Jiao Tong University, Shanghai, China.
Zishu WangAnhui Provincial Key Laboratory of Tumor Evolution and Intelligent Diagnosis and Treatment, Department of Medical Oncology, First Affiliated Hospital of Bengbu Medical University, Bengbu Medical University, Bengbu, Anhui, China.
Lei SunShanghai Frontiers Science Center of Drug Target Identification and Delivery, School of Pharmaceutical Sciences, Shanghai Jiao Tong University, Shanghai, China.
Shulong ZhangDepartment of General Surgery, Xuhui Central Hospital, Shanghai, China.
Huabang ZhouDepartment of Hepatobiliary Medicine, Eastern Hepatobiliary Surgery Hospital, Shanghai, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Berberine (BBR), an isoquinoline alkaloid extracted from

Indexed as

berberinehepatocellular carcinomaIL-4–JAK1–STAT6 axisM2 polarization of macrophagetumor immune microenvironment

Identifiers

PMID41585886
PMCPMC12823884

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.